<span item_type="fundamental" item_id="2a99e89baf5f246a991fb5162f81e30e" counter_id="ST/US/NUWE" env="prod"></span><span item_type="announcement" item_id="582007484854377473" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 2.217 M, missing the estimate of USD 2.5 M.</p><p>EPS: As of FY2025 Q3, the actual value is USD 0.56.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -2.697 M.</p><p></p><h3>Segment Revenue</h3><ul><li>Total revenue for the third quarter of 2025 was $2.2 million, down 6% year-over-year and up 29% sequentially. On a pro-forma basis, revenue grew approximately 7% year-over-year after excluding one-time SeaStar medical revenue and a decrease in international revenue due to international wind-down activities.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1506492/000114036125041591/ef20058643_ex99-1.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Gross margin was 65.2%, compared to 70.0% in the prior year quarter, affected by unfavorable manufacturing utilization.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1506492/000114036125041591/ef20058643_ex99-1.htm"></span></li><li>Operating expenses totaled $4.1 million, up 30% year-over-year, due to increased investment in rebuilding the U.S. sales force and additional investments in sustaining engineering and quality systems.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1506492/000114036125041591/ef20058643_ex99-1.htm"></span></li><li>Operating loss was - $2.7 million, compared to - $1.5 million last year.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1506492/000114036125041591/ef20058643_ex99-1.htm"></span></li><li>Net income for the third quarter was $468,000, compared to $2.358 million in the prior year quarter.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1506492/000114036125041591/ef20058643_ex99-1.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash used in operating activities was - $7.780 million for the nine months ended September 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1506492/000114036125041591/ef20058643_ex99-1.htm"></span></li><li>Net cash used in investing activities was - $102,000 for the nine months ended September 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1506492/000114036125041591/ef20058643_ex99-1.htm"></span></li><li>Net cash provided by financing activities was $5.888 million for the nine months ended September 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1506492/000114036125041591/ef20058643_ex99-1.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>Raised $1.9 million through ATM facility in the quarter.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1506492/000114036125041591/ef20058643_ex99-1.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>The company is focusing on building a more U.S.-driven business and expanding access to ultrafiltration therapy through new CMS codes and product launches. Nuwellis anticipates new market opportunities and growth in 2025 and beyond, although these forward-looking statements are subject to risks and uncertainties.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1506492/000114036125041591/ef20058643_ex99-1.htm"></span></li></ul>

Nuwellis | 8-K: FY2025 Q3 Revenue Misses Estimate at USD 2.217 M